2026年3月，中国创新药领域传来重磅喜讯——一款自主研发的siRNA（小干扰RNA）新药MWX401注射液，正式获得国家药品监督管理局（NMPA）核准签发的《药物临床试验批准通知书》，获批开展原发性高血压的临床试验研究。值得关注的是，该新药创新性融入纳米抗体技术，实现siRNA药物的靶向递送与效能升级，为亿万高血压患者带来全新治疗希望，也推动国产siRNA技术与纳米抗体的协同应用在慢病领域实现重要突破。
In March 2026, the Chinese innovative drug sector received exciting news — MWX401 Injection, an independently developed small interfering RNA (siRNA) novel drug, was officially issued the Clinical Trial Approval Notice by the National Medical Products Administration (NMPA), granting approval for clinical trials in essential hypertension....
In March 2026, the Chinese innovative drug sector received exciting news — MWX401 Injection, an independently developed small interfering RNA (siRNA) novel drug, was officially issued the Clinical Trial Approval Notice by the National Medical Products Administration (NMPA), granting approval for clinical trials in essential hypertension. Notably, this novel drug innovatively integrates nanobody technology to achieve targeted delivery and efficacy enhancement of siRNA drugs, bringing new treatment hope to hundreds of millions of hypertension patients and driving a pivotal breakthrough in the synergistic application of domestic siRNA technology and nanobodies in the field of chronic diseases.
A recent international collaborative research team published a landmark study in the top-tier journal Nature Communications. For the first time, they successfully developed a nanobody (Nb20) targeting a novel brain receptor, the "metabotropic glycine receptor (mGlyR)," and achieved rapid, potent, and long-lasting antidepressant effects in a...
A recent international collaborative research team published a landmark study in the top-tier journal Nature Communications. For the first time, they successfully developed a nanobody (Nb20) targeting a novel brain receptor, the "metabotropic glycine receptor (mGlyR)," and achieved rapid, potent, and long-lasting antidepressant effects in a mouse model through non-invasive intranasal delivery. This research not only validates the tremendous potential of mGlyR as a new antidepressant target but also demonstrates the feasibility of nanobodies as novel biologics for treating brain disorders, offering a new therapeutic paradigm for intractable neuropsychiatric conditions.
So, what are the key findings of this "landmark" study, and what is its mechanism of action?
近期一支国际联合科研团队在顶级期刊《自然·通讯》上发表了一项具有里程碑意义的研究。他们首次成功开发出一种靶向新型大脑受体“代谢型甘氨酸受体（mGlyR）”的纳米抗体（Nb20），并通过非侵入性的鼻内给药方式，在小鼠模型中实现了快速、强效且持久的抗抑郁效果。这项研究不仅验证了mGlyR作为抗抑郁新靶点的巨大潜力，更展示了纳米抗体作为治疗脑部疾病新型生物制剂的可行性，为难以治愈的神经精神疾病带来了全新的治疗范式。
那么，这项被誉为“里程碑”的研究具体取得了哪些关键发现？其作用机制又是怎样的？
In the golden track of cancer immunotherapy, immunotherapy targeting PD-1 (Programmed Death Receptor 1) has become a classic paradigm, but its single-target strategy faces bottlenecks in clinical response rate and drug resistance. With the deepening understanding of tumor immune escape mechanisms, PD-L1 (Programmed Death Ligand 1), as...
In the golden track of cancer immunotherapy, immunotherapy targeting PD-1 (Programmed Death Receptor 1) has become a classic paradigm, but its single-target strategy faces bottlenecks in clinical response rate and drug resistance. With the deepening understanding of tumor immune escape mechanisms, PD-L1 (Programmed Death Ligand 1), as a key ligand of PD-1, has gradually moved from the "background pathway" to the "center stage" and become one of the core targets for a new generation of immune combination therapy and multi-mechanism synergistic intervention. Since the approval of the first inhibitor, it has rewritten the treatment outcomes of countless cancer patients with its clear mechanism of action and broad-spectrum anti-cancer effects. The rise of nanobodies is breaking through its clinical application bottlenecks. Combined with the latest research results in 2026, the potential of this classic target continues to explode.
Today, we follow the R&D context of PD-L1 to discuss its core value, latest breakthroughs, and how nanobodies have become the "key to breaking the deadlock"!